Search results
Results from the WOW.Com Content Network
Antibody Solutions was founded in 1995 by current president, John Kenney, PhD, Judith Lynch-Kenney, and Dennis and Bette Gould. Dr. Kenney previously managed the monoclonal antibody (MAb) development laboratory for Syntex Research in Palo Alto, while Gould managed the MAb production facility for Syva Diagnostics.
Eftilagimod alpha ("efti" in short) is a soluble LAG-3 fusion protein that activates antigen-presenting cells.It is a 160 kDa protein consisting of the four extracellular domains of LAG-3 fused to the Fc region of an IgG1(LAG-3Ig).
Results of a Phase I clinical trial were reported in 2016. [6]In December 2019, enfortumab vedotin was approved in the United States for the treatment of adult patients with locally advanced or metastatic urothelial cancer who had previously received a programmed cell death receptor-1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitor and a platinum-containing chemotherapy.
The first approved medication in this class, tocilizumab (Actemra), is an antibody directed against the IL6-receptor. [8] The second, siltuximab (Sylvant), is directed against IL-6 itself. [ 1 ] [ 9 ] Siltuximab is approved for treatment of human immunodeficiency virus-negative and HHV-8 -negative patients with multicentric Castleman's disease .
Ology Bioservices (previously named Nanotherapeutics, Inc.) is a private, American biopharmaceutical company headquartered in Alachua, Florida.The company was founded with research in nanometer-scale particle technology to develop new drug delivery technologies and increase the efficacy of existing drugs. [3]
The resurrection of antibody immunotherapy contributed to Cesar Milstein and Georges J. F. Kohler, who manifested the mass production of pure monoclonal antibodies with limited adverse effects in 1975. Since then, passive antibody therapy has become prevailed as cancer therapeutics and viral treatments.
Ixekizumab is a complete monoclonal antibody of the subclass IgG 4, consisting of two light chains and two heavy chains linked by disulfide bridges. Both heavy chains are glycosylated at the asparagine in position 296.
Antibody therapy may refer to several different uses of antibodies for the treatment of medical conditions. Monoclonal antibody therapy; Oligoclonal antibody therapy ...